Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2015

01.01.2015 | Clinical trial

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

verfasst von: A. R. Tan, H. Johannes, P. Rastogi, S. A. Jacobs, A. Robidoux, P. J. Flynn, M. P. Thirlwell, L. Fehrenbacher, P. J. Stella, R. Goel, T. B. Julian, L. Provencher, M. J. Bury, K. Bhatt, C. E. Geyer Jr., S. M. Swain, E. P. Mamounas, N. Wolmark

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

This multicenter single-arm phase II study evaluated the addition of pazopanib to concurrent weekly paclitaxel following doxorubicin and cyclophosphamide as neoadjuvant therapy in human epidermal growth factor receptor (HER2)-negative locally advanced breast cancer (LABC). Patients with HER2-negative stage III breast cancer were treated with doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for four cycles every 3 weeks followed by weekly paclitaxel 80 mg/m2 on days 1, 8, and 15 every 28 days for four cycles concurrently with pazopanib 800 mg orally daily prior to surgery. Post-operatively, pazopanib was given daily for 6 months. The primary endpoint was pathologic complete response (pCR) in the breast and lymph nodes. Between July 2009 and March 2011, 101 patients with stage IIIA–C HER2-negative breast cancer were enrolled. The pCR rate in evaluable patients who initiated paclitaxel and pazopanib was 17 % (16/93). The pCR rate was 9 % (6/67) in hormone receptor-positive tumors and 38 % (10/26) in triple-negative tumors. Pre-operative pazopanib was completed in only 39 % of patients. The most frequent grade 3 and 4 adverse events during paclitaxel and pazopanib were neutropenia (27 %), diarrhea (5 %), ALT and AST elevations (each 5 %), and hypertension (5 %). Although the pCR rate of paclitaxel and pazopanib following AC chemotherapy given as neoadjuvant therapy in women with LABC met the pre-specified criteria for activity, there was substantial toxicity, which led to a high discontinuation rate of pazopanib. The combination does not appear to warrant further evaluation in the neoadjuvant setting for breast cancer.
Literatur
2.
Zurück zum Zitat von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309CrossRef von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309CrossRef
3.
Zurück zum Zitat Harris PA, Boloor A, Cheung M et al (2008) Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51:4632–4640PubMedCrossRef Harris PA, Boloor A, Cheung M et al (2008) Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51:4632–4640PubMedCrossRef
4.
Zurück zum Zitat Hurwitz HI, Dowlati A, Saini S et al (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220–4227PubMedCrossRef Hurwitz HI, Dowlati A, Saini S et al (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220–4227PubMedCrossRef
5.
Zurück zum Zitat Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRef Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRef
6.
Zurück zum Zitat van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886PubMedCrossRef van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886PubMedCrossRef
7.
Zurück zum Zitat Tan AR, Dowlati A, Jones SF et al (2010) Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 15:1253–1261PubMedCentralPubMedCrossRef Tan AR, Dowlati A, Jones SF et al (2010) Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 15:1253–1261PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Sargent DJ, Chan V, Goldberg RM (2001) A three-outcome design for phase II clinical trials. Control Clin Trials 22:117–125PubMedCrossRef Sargent DJ, Chan V, Goldberg RM (2001) A three-outcome design for phase II clinical trials. Control Clin Trials 22:117–125PubMedCrossRef
9.
Zurück zum Zitat Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef
10.
Zurück zum Zitat von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676–2685CrossRef von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676–2685CrossRef
11.
12.
Zurück zum Zitat Ein-Gal SY, Tsang W, Alger B et al (2013) Updated interim analysis of UCI 091-53: a phase II, single arm study of pazopanib and paclitaxel as first-line treatment for subjects with unresectable advanced melanoma. J Clin Oncol 31(Suppl):Abstr 9082 Ein-Gal SY, Tsang W, Alger B et al (2013) Updated interim analysis of UCI 091-53: a phase II, single arm study of pazopanib and paclitaxel as first-line treatment for subjects with unresectable advanced melanoma. J Clin Oncol 31(Suppl):Abstr 9082
13.
Zurück zum Zitat Srinivas S, Narayanan S, Harsham LC et al (2014) Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer. J Clin Oncol 32(Suppl):Abstr 299 Srinivas S, Narayanan S, Harsham LC et al (2014) Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer. J Clin Oncol 32(Suppl):Abstr 299
14.
Zurück zum Zitat Seidman AD, Hudis CA, Albanell J et al (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353–3361PubMed Seidman AD, Hudis CA, Albanell J et al (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353–3361PubMed
15.
Zurück zum Zitat Bible KC, Suman VJ, Molina JR et al (2014) A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 99:1687–1693PubMedCrossRef Bible KC, Suman VJ, Molina JR et al (2014) A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 99:1687–1693PubMedCrossRef
16.
Zurück zum Zitat Taylor SK, Chia S, Dent S et al (2010) A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 15:810–818PubMedCentralPubMedCrossRef Taylor SK, Chia S, Dent S et al (2010) A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 15:810–818PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Yardley D, Barton J, Hendricks C et al (2012) Neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer: preliminary results from a phase I/II trial of the Sarah Cannon Research Institute. Cancer Res 72(Suppl):Abstr P1-14-14 Yardley D, Barton J, Hendricks C et al (2012) Neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer: preliminary results from a phase I/II trial of the Sarah Cannon Research Institute. Cancer Res 72(Suppl):Abstr P1-14-14
Metadaten
Titel
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study
verfasst von
A. R. Tan
H. Johannes
P. Rastogi
S. A. Jacobs
A. Robidoux
P. J. Flynn
M. P. Thirlwell
L. Fehrenbacher
P. J. Stella
R. Goel
T. B. Julian
L. Provencher
M. J. Bury
K. Bhatt
C. E. Geyer Jr.
S. M. Swain
E. P. Mamounas
N. Wolmark
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3221-2

Weitere Artikel der Ausgabe 1/2015

Breast Cancer Research and Treatment 1/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.